<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Madrigal Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc</link>
<description>Latest news and press releases for Madrigal Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 27 May 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/madrigal-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683596fb78dffbe2df104cad.webp</url>
<title>Madrigal Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc</link>
</image>
<item>
<title>Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-presents-data-demonstrating-rezdiffra-reduced-markers-of-cardiovascular-and-liver-related-risk-in-patients-with-mash</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-presents-data-demonstrating-rezdiffra-reduced-markers-of-cardiovascular-and-liver-related-risk-in-patients-with-mash</guid>
<pubDate>Wed, 27 May 2026 12:00:00 GMT</pubDate>
<description>Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associated with cardiovascular risk, including LDL-C, ApoB and Lp(a), in a secondary analysis from the Phase 3 MAESTRO program In patients with well-compensated MASH cirrhosis (F4c), Rezdiffra improved a risk score – ANTICIPATE-NASH – that predicts the probability of experiencing severe liver-related eventsM</description>
</item>
<item>
<title>Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-to-present-new-data-from-the-companys-mash-program-at-easl-2026-demonstrating-the-effects-of-rezdiffra-on-markers-of-cardiovascular-and-portal-hypertension-risk</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-to-present-new-data-from-the-companys-mash-program-at-easl-2026-demonstrating-the-effects-of-rezdiffra-on-markers-of-cardiovascular-and-portal-hypertension-risk</guid>
<pubDate>Wed, 20 May 2026 12:00:00 GMT</pubDate>
<description>Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in patients with compensated MASH cirrhosis (F4c) examines improvement in ANTICIPATE-NASH risk scores, a marker for clinically significant portal hypertensionAdditional abstracts focus on early real-world evidence with Rezdiffra and the ability of noninvasive biomarkers to predict fibrosis improvement i</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-corporate-updates</guid>
<pubDate>Wed, 06 May 2026 04:00:00 GMT</pubDate>
<description>First-quarter 2026 Rezdiffra® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127%As of March 31, 2026, more than 42,250</description>
</item>
<item>
<title>Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline</guid>
<pubDate>Tue, 05 May 2026 12:00:00 GMT</pubDate>
<description>Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASHPhase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profileMadrigal’s pipeline includes more than 10 programs at multiple stages of developme</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-to-release-first-quarter-2026-financial-results-and-host-webcast-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-to-release-first-quarter-2026-financial-results-and-host-webcast-on-may-6-2026</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmace</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSW</description>
</item>
<item>
<title>Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-expands-mash-pipeline-exclusive-100000355</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-expands-mash-pipeline-exclusive-100000355</guid>
<pubDate>Wed, 11 Feb 2026 10:00:00 GMT</pubDate>
<description>Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRNA therapies that silence genes implicated in MASH CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-release-fourth-quarter-130500791</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-release-fourth-quarter-130500791</guid>
<pubDate>Mon, 02 Feb 2026 13:05:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Ma</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-grants-inducement-210500933</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-grants-inducement-210500933</guid>
<pubDate>Thu, 22 Jan 2026 21:05:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accorda</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-grant-inducement-210500588</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-grant-inducement-210500588</guid>
<pubDate>Wed, 21 Jan 2026 21:05:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted an equity award on January 15, 2026 to Rita Thakkar, the company’s new Chief Accounting Officer, as an equity inducement award under the terms of Madrigal’s 2025 Inducement Plan. The equity award was approved by Madrigal’s Board of Directo</description>
</item>
<item>
<title>Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-expands-its-mash-pipeline-exclusive-global-license-agreement-ervogastat</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-expands-its-mash-pipeline-exclusive-global-license-agreement-ervogastat</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2025-12</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-participation-three-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-announces-participation-three-upcoming-investor-conferences</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in</description>
</item>
<item>
<title>Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-presents-new-data-demonstrating-rezdiffrar-resmetirom-significantly-improved</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-presents-new-data-demonstrating-rezdiffrar-resmetirom-significantly-improved</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients</description>
</item>
<item>
<title>Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing</description>
</item>
<item>
<title>Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-present-new-data-companys-mash-program-aaslds-liver-meeting-2025-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-present-new-data-companys-mash-program-aaslds-liver-meeting-2025-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-release-third-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-release-third-quarter-2025-financial-results-and-host</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel</description>
</item>
<item>
<title>Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-participate-morgan-stanley-23rd-annual-global-healthcare</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-pharmaceuticals-participate-morgan-stanley-23rd-annual-global-healthcare</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the</description>
</item>
<item>
<title>Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis</title>
<link>https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-receives-european-commission-approval-rezdiffratm-resmetirom-treatment-mash</link>
<guid isPermaLink="true">https://6ix.com/company/madrigal-pharmaceuticals-inc/news/madrigal-receives-european-commission-approval-rezdiffratm-resmetirom-treatment-mash</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive</description>
</item>
</channel>
</rss>